author-photo

Marcin Kowanetz

Genentech

131

Papers

14780

Citations

Citation Trend

Filter By

Papers (83) Sort By

Journal Conference Others

C-reactive protein reduction post treatment is associated with improved survival in atezolizumab (anti-PD-L1) treated non-small cell lung cancer patients.

2021 PLOS ONE
Show All
- Source
- Cite
- Save
Citations (0)
Abstract CT218: Phase 1/2 study of a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), BDC-1001, alone and in combination with pembrolizumab (pembro) in patients (pts) with HER2-expressing advanced solid tumors

2021 Clinical Trials
Show All
- Source
- Cite
- Save
Citations (0)
Abstract OT-03-02: Phase 1/2 study of a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), BDC-1001, as a single agent and in combination with an immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (2)
784 BDC-2034: discovery of a CEA-targeting immune-stimulating antibody conjugate (ISAC) for solid tumors

2021 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade.

2021 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (5)
862 Dectin-2, a novel target for tumor macrophage reprogramming in cancer immunotherapy

2021 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
401 Phase 1/2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 with or without immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors

2020 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (2)
605 Systemically administered HER2-targeted ISACs provoke a rapid, local response that engages the innate and adaptive arms of the immune system to eradicate tumors in preclinical models

2020 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Clinical Activity and Safety of Atezolizumab in a Phase 1 Study of Patients With Relapsed/Refractory Small-Cell Lung Cancer

2020 Clinical Lung Cancer
Show All
- Source
- Cite
- Save
Citations (6)
Immune Signaling in Carcinogenesis

2019
Show All
- Source
- Cite
- Save
Citations (2)